Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
MESA LABORATORIES INC /CO/
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-86.2% vs price
Base Case (Median)
-80.5% vs price
Bull Case (75th pct.)
-56.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $13.90 | -89.2% | High (40%) |
| PE Comparable | $21.66 | -83.2% | Medium (25%) |
| Growth Trajectory DCF | $43.28 | -66.4% | Medium (20%) |
| Graham Number | $25.09 | -80.5% | Low (10%) |
| EV/EBITDA | $67.54 | -47.5% | Medium (20%) |
| EV/FCF | $186.93 | 45.3% | Medium (20%) |
| Earnings Power Value | $9.79 | -92.4% | Medium (50%) |
Based on 7 out of 8 methods, MLAB appears overvalued at the current price of $128.65. The base case fair value of $25.09 implies 80.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.
